Glaxosmithkline Share News (GSK)

AGM, EGM Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

UPDATE 1-Nexium, Advair led Medicare drug spending in 2013 -officials

(New throughout, adds more prescribing data and details of neurology drug price rise) By Sharon Begley NEW YORK, April 30 (Reuters) - Four brand-name medications accounted for almost one-tenth of the $103 billion in prescriptions filled by older or disabled Americans under Medicare's

Nexium, Advair led Medicare drug spending in 2013 - officials

By Sharon Begley NEW YORK, April 30 (Reuters) - Four brand-named drugs prescribed to older or disabled Americans covered by Medicare's drug benefit accounted for almost one-tenth of the $103 billion in prescriptions filled under the plan in 2013, U.S. officials reported on Thursday. T

GSK's Nigerian unit says Q1 pretax profit falls 53 pct

LAGOS, April 30 (Reuters) - GSK's Nigerian unit said on Thursday its first-quarter pretax profit fell 52.7 percent to 421.83 million naira ($2 million), from a year earlier. Revenue also fell to 7.45 billion naira in the period to end-March from 7.80 billion naira last year, the pharmaceut

AGM, EGM Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

Wednesday broker round-up

Sky: JP Morgan reiterates neutral stance and 1,170p target. GlaxoSmithKline: UBS reiterates buy and 1,700p target. StanChart: Nomura reiterates neutral and lifts target to 1,170p from 1,030p. UBS reiterates neutral stance with 1,000p target. Henderson Group: Citi reiterates buy with 3,250p target.

Earnings, Trading Statements Calendar - Week Ahead

LONDON MARKET COMMENT: Stocks Seen Up Ahead Of US GDP, Fed Decision

LONDON MARKET COMMENT: Stocks Called To Rebound With US Fed In Focus

Earnings, Trading Statements Calendar - Week Ahead

Biotechs seek cross-over to public markets

By Robert Sherwood NEW YORK, April 28 (IFR) - Early-stage biotech companies continue to find a favorable bid in both the private and public markets. Continuing the trend of late-stage crossover rounds, Adaptimmune Therapeutics and aTyr Pharma are looking to follow up recent private institut

LONDON MARKET CLOSE: FTSE 100 Reverses Three Days Of Gains